Boost your inner glow and optimize your output with these IV drips to prep you pre-summer and post-summer shine.

Results from a randomized, phase 2 clinical trial show that adding high-dose, intravenous (IV) vitamin C to chemotherapy ...

Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in ...

A randomized, phase 2 clinical trial shows that adding high-dose, intravenous (IV) vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic pancreatic cancer from ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...

There has been a rise in these types of hydration clinics opening more throughout the country and in the Birmingham area in ...

US pharma giant Merck & Co (NYSE: MRK) today announced positive top-line results from the pivotal Phase III MK-3475A-D77 ...

The phase 3 trial met both primary pharmacokinetic endpoints. Topline results were announced from a phase 3 trial investigating a subcutaneous formulation of pembrolizumab, a programmed death receptor ...

Results from a randomized phase 2 clinical trial show that adding high-dose, intravenous (IV) vitamin C to chemotherapy ...

Intravenous iron therapy improves symptoms in patients with heart failure (HF) and iron deficiency (ID), but the impact on cardiovascular outcomes remains inconsistent. Researchers conducted a ...